In the BioHarmony Drug Report Database

"Preview" Icon

Abatacept

Orencia (abatacept) is a protein pharmaceutical. Abatacept was first approved as Orencia on 2005-12-23. It is used to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.

 

Trade Name

 

Orencia
 

Common Name

 

abatacept
 

ChEMBL ID

 

CHEMBL1201823
 

Indication

 

juvenile arthritis, psoriatic arthritis, rheumatoid arthritis
 

Drug Class

 

Receptor molecules, native or modified: T-cells

Image (chem structure or protein)

Abatacept structure rendering